<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769899</url>
  </required_header>
  <id_info>
    <org_study_id>D1140C00010</org_study_id>
    <nct_id>NCT00769899</nct_id>
  </id_info>
  <brief_title>AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects</brief_title>
  <acronym>JSAD</acronym>
  <official_title>A Phase I,Single-Center,Randomised,Double-Blind,Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7325 in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I randomized double-blind, placebo-controlled, single centre study to assess
      the safety, tolerability and pharmacokinetics of AZD7325 following single ascending dose
      administration to healthy male Japanese volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerabilityThe nature and incidence of adverse events (AEs), vital signs,physical examinations,electrocardiograms (ECGs)and laboratory assessments.</measure>
    <time_frame>During the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters for AZD7325</measure>
    <time_frame>During residential period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic analysis of the genes involved in the pharmacokinetics and safety and tolerability to AZD7325 treatment may be performed. Participation in the exploratory genetic study is optional for the subjects.</measure>
    <time_frame>During the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7325</intervention_name>
    <description>Capsule for oral, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule for oral, single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) : 18 to 27 kg/m 2

        Exclusion Criteria:

          -  Clinically relevant disease and/or abnormalities (past or present)

          -  Clinically relevant abnormalities in physical examinations,vital signs,clinical
             chemistry, hematology or urinalysis at screening as judged by the investigator

          -  Use of any medication or herbal preparation within 14 days of Study day 1 through the
             Follow-up Visit other than paracetamol (up to 3 g/day)

          -  Smoking in excess of 5 cigarettes per day or the equivalent within 28 days prior to
             the first study day or inability to refrain from smoking during the study confinement
             period
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Yen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>March 17, 2009</last_update_submitted>
  <last_update_submitted_qc>March 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark A. Smith, MD, PhD Senior Medical Science Director</name_title>
    <organization>AstraZeneca LP</organization>
  </responsible_party>
  <keyword>AZD7325</keyword>
  <keyword>Japanese Healthy Volunteers</keyword>
  <keyword>Phase I study</keyword>
  <keyword>Single Ascending Dose</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

